AskMed

Psoriasis: Types, Causes, Severity and Treatment

Psoriasis is a chronic, immune-mediated inflammatory disease that mainly shows on the skin as red or darker, raised, scaly patches, and it is not contagious. About 125 million people have it worldwide and 3.0% of adults in the United States. Plaque psoriasis is by far the most common form, but there are several others, and the disease reaches beyond the skin: it is linked to psoriatic arthritis, cardiometabolic disease and depression. This guide covers the types, the IL-23 and IL-17 pathway that drives the plaques, common triggers, how severity is graded with body surface area and PASI, the conditions that travel with psoriasis, the treatment classes by name, and when to see a doctor. Every figure links to its source.

Psoriasis care rests on guidelines that do not always agree: NICE in the UK and the joint American Academy of Dermatology and National Psoriasis Foundation (AAD-NPF) guidelines in the US set different thresholds for starting a biologic. AskMed is a medical question app for doctors, nurses, pharmacists, medical students and researchers that searches journals, clinical guidelines and drug labels first, then writes an answer with a link after every claim. For a resident preparing a dermatology clinic or a student revising for finals, that means asking, for example, which comorbidities the AAD-NPF comorbidity guideline says to screen for in newly diagnosed plaque psoriasis, and reading each recommendation next to its source.

Check the psoriasis guidelines in AskMed:

What is psoriasis, and what drives it in the immune system?

Psoriasis is a chronic inflammatory disease in which an overactive immune response makes skin cells multiply far faster than normal. The National Psoriasis Foundation explains that normal skin cells grow and shed in about a month, while in psoriasis they do so in three or four days, so instead of shedding they pile up into thick, scaly plaques. A 2017 review in the Journal of Allergy and Clinical Immunology by Hawkes, Chan and Krueger describes psoriasis as a T cell-mediated disease driven mainly by T cells that produce high levels of interleukin 17 (IL-17) in response to IL-23. IL-17 then sets off a self-amplifying, feed-forward loop in keratinocytes that thickens the epidermis and draws more white cells into the skin. Genes matter too: the 2021 Lancet seminar by Griffiths and colleagues names the HLA-C*06:02 risk allele as a key genetic susceptibility factor, and notes that IL-17, IL-23 and TNF-α are the cytokines today's biologics target.

Pathway Drug class that blocks it Genes + triggers HLA-C*06:02, infections IL-23 drives type 17 T cells IL-23 p19 inhibitors IL-12/23 p40 inhibitor IL-17 released by T cells IL-17 inhibitors TNF-α amplifies inflammation TNF-α inhibitors Skin cells multiply 3–4 days, not a month
The IL-23/IL-17 axis (Hawkes 2017; Griffiths 2021) and the biologic classes named in the 2020 JAMA review by Armstrong and Read. Skin turnover figures from the National Psoriasis Foundation.

Psoriasis usually starts in one of two age windows: the NHS gives 15 to 25 and 50 to 60 years, although it can begin at any age. It runs in families, and it is not infectious, so it cannot be caught or passed on by touch.

What are the types of psoriasis?

The main types of psoriasis are plaque, guttate, inverse, pustular and erythrodermic psoriasis, and nail psoriasis can occur with any of them. Plaque psoriasis, also called psoriasis vulgaris, accounts for about 80 to 90% of people with the disease, according to the National Psoriasis Foundation. The American Academy of Dermatology describes its patches as thick, raised and covered with silvery scale, usually on the scalp, elbows, knees and lower back; the NHS notes that on brown or black skin the patches can look grey, can leave dark marks, and that redness is harder to see. Guttate psoriasis causes many small, scaly spots and often appears in children after an infection such as strep throat. Inverse psoriasis forms smooth, shiny, often bright red patches where skin touches skin, such as the armpits and groin. Pustular psoriasis causes pus-filled blisters, most often on the hands and feet, and erythrodermic psoriasis makes large areas of skin look burnt.

A person can have more than one type at once, or different types over a lifetime, and the type and site guide the choice of treatment.

What triggers psoriasis or makes it flare?

Psoriasis triggers are everyday exposures that bring out psoriasis for the first time in someone with a genetic tendency, or make existing plaques flare. The Lancet seminar lists streptococcal infection, stress, smoking, obesity and alcohol as environmental triggers of plaque psoriasis, and the NHS adds pregnancy, certain medicines, HIV infection, sunlight and skin injury. The American Academy of Dermatology gives useful timings: psoriasis can flare 2 to 6 weeks after strep throat, an earache or bronchitis, especially in children; new plaques can appear about 10 to 14 days after a cut, scrape, scratch, sunburn or bug bite, at the site of the injury, and tattoos and piercings count as skin injury too; and a medicine that triggers psoriasis usually does so 2 to 3 weeks after it is started. Medicines the academy names include lithium, antimalarials such as hydroxychloroquine, some drugs for high blood pressure and heart rhythm problems, and oral corticosteroids such as prednisone when they are stopped abruptly.

Because a suspected trigger medicine may be essential, the AAD advises people not to stop it on their own but to ask the prescriber whether it could be the cause and whether an alternative exists. Treating an infection can lessen or clear the flare it set off.

How is psoriasis severity judged?

Psoriasis severity is judged by combining how much skin is involved, how inflamed the plaques are and how much the disease affects daily life. Body surface area (BSA) is the percentage of the skin that has psoriasis. The Psoriasis Area and Severity Index (PASI) combines the redness, thickness and scaling of plaques with the area affected, and ranges from 0 to 72. The static Physician's Global Assessment grades the overall picture from clear to very severe, and the Dermatology Life Quality Index (DLQI) measures the impact on the person. A European consensus led by Mrowietz in 2011 defined mild plaque psoriasis as BSA 10 or under, PASI 10 or under and DLQI 10 or under, and moderate to severe as BSA or PASI above 10 with a DLQI above 10. NICE CG153 uses more than 10% of body surface area as an example of severe or extensive disease, and recommends PASI in specialist settings.

  1. BSA: share of the skin involved; NICE gives more than 10% as an example of extensive disease.
  2. PASI: redness, thickness, scaling and area, scored 0 to 72; above 10 is moderate to severe.
  3. Physician's Global Assessment: clear, nearly clear, mild, moderate, severe or very severe.
  4. DLQI: impact on daily life; above 10 means a significant effect.
The four measures named in NICE CG153 and the 2011 European consensus. PASI and BSA are not validated for children and young people (NICE).

Both sources treat nail disease and high-impact sites such as the face, scalp, palms, soles and genitals as reasons to treat mild-looking psoriasis more actively. The same scores also define treatment response. For conventional systemic drugs, NICE gives as an example of an adequate response a fall in PASI of at least 75% (PASI 75), or of at least 50% together with a DLQI improvement of at least 5 points. Severity definitions differ enough between NICE, the European consensus and the AAD-NPF guidelines that it is worth checking which one a paper or local pathway uses. In AskMed, a dermatology trainee can ask how NICE and the AAD-NPF guidelines each define moderate to severe plaque psoriasis and where they draw the line for systemic treatment, and get both answers side by side, each linked to the guideline section it comes from.

Compare severity definitions in AskMed:

Which conditions are linked to psoriasis?

The conditions most strongly linked to psoriasis are psoriatic arthritis, cardiometabolic disease and depression, which is why the AAD-NPF published a separate 2019 guideline on comorbidities. Psoriatic arthritis is the most common: a 2019 meta-analysis by Alinaghi and colleagues of 266 studies and 976,408 patients found psoriatic arthritis in 19.7% of people with psoriasis, and 3.3% of children and adolescents. NICE recommends assessing for psoriatic arthritis every year, especially in the first 10 years after psoriasis begins, with a validated tool such as the Psoriasis Epidemiological Screening Tool (PEST), and referring to a rheumatologist as soon as it is suspected. On the cardiometabolic side, a 2013 meta-analysis by Armstrong and colleagues found that people with psoriasis had 2.26 times the odds of metabolic syndrome, with higher odds in more severe disease. In a large UK cohort, Gelfand and colleagues found that a 30-year-old with severe psoriasis had an adjusted relative risk of myocardial infarction of 3.10 compared with people without psoriasis.

19.7%of people with psoriasis have psoriatic arthritis (Alinaghi 2019)
2.26odds ratio for metabolic syndrome (Armstrong 2013)
3.10adjusted relative risk of heart attack at age 30 with severe psoriasis (Gelfand 2006)
28%have depressive symptoms; 12% clinical depression by ICD codes (Dowlatshahi 2014)

Mental health is part of the picture. A 2014 meta-analysis of 98 studies by Dowlatshahi and colleagues found depressive symptoms in 28% of people with psoriasis and clinical depression in 12% by diagnostic codes, and population studies showed at least one and a half times the odds of depression compared with controls. NICE advises asking about depression when assessing severity and whenever treatment is stepped up; a validated questionnaire such as the PHQ-9 can help. NICE also recommends a cardiovascular risk assessment at presentation for adults with severe psoriasis, repeated at least every 5 years, flags psoriasis as a risk factor for venous thromboembolism, and lists severe or atypical psoriasis as an HIV indicator condition. The NHS adds inflammatory bowel disease such as Crohn's disease.

How is psoriasis treated?

Psoriasis treatment is stepped by severity, site and impact: topical treatment first, then phototherapy, conventional systemic drugs and targeted treatments when the skin is not controlled. The 2020 JAMA review by Armstrong and Read lists the topical options for mild disease as corticosteroids, vitamin D analogues, calcineurin inhibitors and keratolytics, and NICE adds coal tar and short-contact dithranol, while warning against potent corticosteroids on the face, flexures and genitals. For more extensive disease, NICE recommends narrowband ultraviolet B phototherapy. The conventional systemic drugs are methotrexate, NICE's usual first choice, ciclosporin and acitretin, which NICE also considers for pustular forms. Targeted treatments include oral small molecules such as apremilast, a phosphodiesterase 4 inhibitor, and deucravacitinib, and the biologics. The AAD-NPF guidelines recommend biologics as an option for first-line treatment of moderate to severe plaque psoriasis, while NICE reserves them for a PASI of 10 or more and a DLQI above 10 after conventional systemic treatment and phototherapy have failed or cannot be used.

Choosing among these classes depends on more than the skin. NICE asks prescribers to manage people with both psoriasis and psoriatic arthritis together with a rheumatologist, and the JAMA review notes that TNF-α, IL-12/23 and IL-17 inhibitors are also approved for psoriatic arthritis. Comorbidities, pregnancy plans, infections such as HIV and cost all shape the decision, and NICE says that when several options suit, the least expensive should be used. These are the questions where a cited answer saves time: in AskMed, a clinician can ask which biologic classes the guidelines favour for plaque psoriasis with coexisting inflammatory bowel disease, or what screening the AAD-NPF biologic guideline recommends before the first injection, and check each point against the guideline and drug label it links to.

Ask AskMed how comorbidities change the choice of biologic:

When should someone with psoriasis see a doctor?

Anyone with possible psoriasis should see a doctor, because the diagnosis is usually made by examining the skin, and the National Psoriasis Foundation notes that treatment can improve symptoms and may lower the risk of comorbidities. The NHS advises seeing a GP for symptoms of psoriasis, when treatment is not working or causes side effects, and for joint pain, stiffness and swelling that keep coming back, which can signal psoriatic arthritis. Some signs need emergency care the same day. The NHS lists skin that quickly turns red with white pus-filled bumps that join together, patches on the feet that turn yellow-brown and fill with pus, and red, scaly pus-filled bumps on the tips of the fingers and toes, especially with a fast heartbeat, fever or shivering. The American Academy of Dermatology says skin that looks burnt over large areas, a sign of erythrodermic psoriasis, needs a doctor immediately. NICE asks for same-day specialist assessment for both generalized pustular psoriasis and erythroderma.

NICE also lists when a non-specialist should refer to dermatology: diagnostic uncertainty, severe or extensive disease, psoriasis that topical treatment cannot control, acute guttate psoriasis that needs phototherapy, nail disease with a major functional or cosmetic impact, or a major effect on physical, psychological or social wellbeing. Children and young people with any type of psoriasis are referred at presentation.

Frequently asked questions

Is psoriasis contagious?

No. Psoriasis is an immune-mediated disease, not an infection, so it cannot be passed on by touch, swimming or sex. An infection such as strep throat can trigger guttate psoriasis, but the psoriasis itself does not spread between people.

Can psoriasis be cured?

Not at present. Psoriasis is usually lifelong, with flares and quieter periods, although some children with guttate psoriasis never have it again. Modern treatments, especially biologics for moderate to severe disease, can clear or nearly clear the skin in many people.

What is the difference between psoriasis and plaque psoriasis?

Psoriasis is the disease; plaque psoriasis, or psoriasis vulgaris, is its most common type, seen in 80 to 90% of people with psoriasis. The other types are guttate, inverse, pustular and erythrodermic psoriasis, and nail psoriasis can occur with any of them.

What is a PASI score?

The Psoriasis Area and Severity Index scores redness, thickness and scaling together with the area affected, from 0 to 72. A PASI above 10 is generally taken as moderate to severe, and a 75% fall from baseline (PASI 75) is a common measure of treatment response.

How often does psoriasis lead to psoriatic arthritis?

A 2019 meta-analysis of 266 studies found psoriatic arthritis in 19.7% of people with psoriasis. NICE recommends checking for it every year, especially in the first 10 years after psoriasis starts.

Sources

  1. National Institute for Health and Care Excellence. Psoriasis: assessment and management (CG153), Recommendations. NICE; 2012, with later updates.
  2. Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029-1072.
  3. Elmets CA, Leonardi CL, Davis DMR, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. J Am Acad Dermatol. 2019;80(4):1073-1113.
  4. Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA. 2020;323(19):1945-1960.
  5. Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker JNWN. Psoriasis. Lancet. 2021;397(10281):1301-1315.
  6. Armstrong AW, Mehta MD, Schupp CW, et al. Psoriasis prevalence in adults in the United States. JAMA Dermatol. 2021;157(8):940-946.
  7. Hawkes JE, Chan TC, Krueger JG. Psoriasis pathogenesis and the development of novel targeted immune therapies. J Allergy Clin Immunol. 2017;140(3):645-653.
  8. Alinaghi F, Calov M, Kristensen LE, et al. Prevalence of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational and clinical studies. J Am Acad Dermatol. 2019;80(1):251-265.
  9. Armstrong AW, Harskamp CT, Armstrong EJ. Psoriasis and metabolic syndrome: a systematic review and meta-analysis of observational studies. J Am Acad Dermatol. 2013;68(4):654-662.
  10. Gelfand JM, Neimann AL, Shin DB, et al. Risk of myocardial infarction in patients with psoriasis. JAMA. 2006;296(14):1735-1741.
  11. Dowlatshahi EA, Wakkee M, Arends LR, Nijsten T. The prevalence and odds of depressive symptoms and clinical depression in psoriasis patients: a systematic review and meta-analysis. J Invest Dermatol. 2014;134(6):1542-1551.
  12. Mrowietz U, Kragballe K, Reich K, et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res. 2011;303(1):1-10.
  13. Maul JT, Maul LV, Didaskalu JA, et al. Correlation between Dermatology Life Quality Index and Psoriasis Area and Severity Index in patients with psoriasis. Acta Derm Venereol. 2024;104:adv20329.
  14. NHS. Psoriasis. Page last reviewed 10 March 2026.
  15. American Academy of Dermatology. What does psoriasis look like?, Causes of psoriasis and Are triggers causing your psoriasis flare-ups?
  16. National Psoriasis Foundation. About psoriasis.

Cited medical answers
you can trust.

AskMed on iPhone, iPad, Android and the web.